HSA-Lys-161 covalent bound fluorescent dye for <i>in vivo</i> blood drug dynamic imaging and tumor mapping

Yue, Yongkang; Zhao, Tingting; Wang, Yuting; Ma, Kewei; Wu, Xingkang; Huo, Fangjun; Cheng, Fangqin; Yin, Caixia

doi:10.1039/d1sc05484h

Cited by 20 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In 2022, our research group reported turn-on fluorescent probe 98 (SS-1) covalently bound to albumin (Figure 29), which enabled long-term and real-time fluorescence detection during in vivo imaging. 162 At the same time, 98-labeled HSA as a conjugated fluorescent probe interacted with the drug and caused a significant increase in fluorescence. This was the first in situ monitoring of the ibuprofen concentration in blood by fluorescence analysis.…”

Section: Probe Combined With Hsa For Optical Imaging and Therapymentioning

confidence: 99%

Development of Human Serum Albumin Fluorescent Probes in Detection, Imaging, and Disease Therapy

Wang,

Huo,

Yin

2024

J. Phys. Chem. B

Self Cite

View full text Add to dashboard Cite

Human serum albumin (HSA) acts as a repository and transporter of substances in the blood. An abnormal concentration may indicate the occurrence of liver-and kidney-related diseases, which has attracted people to investigate the precise quantification of HSA in body fluids. Fluorescent probes can combine with HSA covalently or noncovalently to quantify HSA in urine and plasma. Moreover, probes combined with HSA can improve its photophysical properties; probe-HSA has been applied in real-time monitoring and photothermal and photodynamic therapy in vivo. This Review will introduce fluorescent probes for quantitative HSA according to the three reaction mechanisms of spatial structure, enzymatic reaction, and self-assembly and systematically introduce the application of probes combined with HSA in disease imaging and phototherapy. It will help develop multifunctional applications for HSA probes and provide assistance in the early diagnosis and treatment of diseases.

show abstract

Section: Probe Combined With Hsa For Optical Imaging and Therapymentioning

confidence: 99%

Development of Human Serum Albumin Fluorescent Probes in Detection, Imaging, and Disease Therapy

Wang,

Huo,

Yin

2024

J. Phys. Chem. B

Self Cite

View full text Add to dashboard Cite

show abstract

“…Methods such as immunochemistry, protein mass spectrometry, bromocresol green (BCG), and bromocresol purple (BCP) have been developed for the quantitative detection of HSA, but they suffer from complicated operation and are costly. − Fluorescence sensing and imaging is a noninvasive detection approach that has become popular in recent decades, especially in small-molecule-based probes that exhibit the advantages of high sensitivity, selectivity, multicolor imaging, high background contrast with high signal-to-noise ratio in situ , etc. To date, the small-molecular fluorescent probes developed for HSA can be categorized into noncovalent and covalent binding modes. ,− It has been suggested that covalent binding exhibits better selectivity and stability to resist interference from small biomolecules and drugs. ,,, Ajayaghosh et al developed self-assembling dyes that form nonfluorescent nanoparticles, and HSA can selectively disassemble and covalently bind to generate a fluorescent response . He et al orthogonally functionalized HSA using covalent and supramolecular approaches to modular peptides, achieving specific optical visualization and photodynamic ablation of malignant liver tumors of human origin .…”

Section: Introductionmentioning

confidence: 99%

A Rationally Designed Prodrug for the Fluorogenic Labeling of Albumin and Theranostic Effects on Drug-Induced Liver Injury

Wu,

Zhang,

Zhang

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

The development of small-molecular fluorogenic tools for the chemo-selective labeling of proteins in live cells is important for the evaluation of intracellular redox homeostasis. Dynamic imaging of human serum albumin (HSA), an antioxidant protein under oxidative stress with concomitant release of antioxidant drugs to maintain redox homeostasis, affords potential opportunities for disease diagnosis and treatment. In this work, we developed a nonfluorogenic prodrug named TPA-NAC, by introducing N-acetyl-L-cysteine (NAC) into a conjugated acceptor skeleton. Through combined thiol and amino addition, coupling with HSA results in fluorescence turn-on and drug release. It was reasoned that the restricted intramolecular motion of the probe under an HSA microenvironment after covalent bonding inhibited the nonradiative transitions. Furthermore, the biocompatibility and photochemical properties of TPA-NAC enabled it to image exogenous and endogenous HSA in living cells in a wash-free manner. Additionally, the released drug evoked upregulation of superoxide dismutase (SOD), which synergistically eliminated reactive oxygen species in a drug-induced liver injury model. This study provides insights into the design of new theranostic fluorescent prodrugs for chemo-selective protein labeling and disease treatments.

show abstract

“…Only a few of them exhibit the potential to probe the drug binding site on HSA (Table S1†). 14 For example, Zhen Zou et al have recently presented a perylenediimide probe that can specifically target the binding site of an anti-convulsion drug tiagabine hydrochloride (TGB) on HSA, resulting in significant fluorescence changes. On this basis, a fluorescence assay has been developed for quantitatively analyzing TGB.…”

Section: Introductionmentioning

confidence: 99%

Probing the serum albumin binding site of fenamates and photochemical protein labeling with a fluorescent dye

et al. 2022

View full text Add to dashboard Cite

show abstract

HSA-Lys-161 covalent bound fluorescent dye for in vivo blood drug dynamic imaging and tumor mapping

Abstract: The specific combination of human serum albumin and fluorescent dye will endow superior performance to the coupled fluorescent platform for in vivo fluorescence labeling. In this study, we found that...

Cited by 20 publications

References 30 publications

Development of Human Serum Albumin Fluorescent Probes in Detection, Imaging, and Disease Therapy

Development of Human Serum Albumin Fluorescent Probes in Detection, Imaging, and Disease Therapy

A Rationally Designed Prodrug for the Fluorogenic Labeling of Albumin and Theranostic Effects on Drug-Induced Liver Injury

Probing the serum albumin binding site of fenamates and photochemical protein labeling with a fluorescent dye

Contact Info

Product

Resources

About